{"id":60375,"date":"2021-10-06T13:03:22","date_gmt":"2021-10-06T11:03:22","guid":{"rendered":"http:\/\/www.veeva.com\/eu\/?post_type=resources&p=60375"},"modified":"2026-04-09T18:49:57","modified_gmt":"2026-04-09T16:49:57","slug":"celerion-transforms-the-consent-experience-for-sites-and-patients-with-veeva-econsent","status":"publish","type":"resources","link":"https:\/\/pantheon.veeva.com\/eu\/resources\/celerion-transforms-the-consent-experience-for-sites-and-patients-with-veeva-econsent\/","title":{"rendered":"Celerion Transforms the Consent Experience for Sites and Patients with Veeva eConsent"},"content":{"rendered":"

Veeva eConsent simplifies patient informed consent
for greater efficiency and compliance <\/em><\/p>\n

BARCELONA, Spain \u2014 6 Oct. 2021 \u2014<\/strong> Veeva Systems<\/a> (NYSE: VEEV) today announced that Celerion adopted Veeva eConsent<\/a>, a MyVeeva for Patients<\/a> solution, to complete electronic consent for its Phase I clinical trials. With Veeva eConsent, Celerion is shifting from manual and paper-based informed consent to a completely digital process. The company is using Veeva eConsent across multiple studies and has consented more than 200 subjects. <\/p>\n

\u201cCOVID-19 limited our time with participants, so we needed new and digital ways to keep our studies moving forward while remaining fully compliant with regulatory requirements regarding obtaining proper consent,\u201d said Staci McDonald, executive director, scientific clinical operations at Celerion. \u201cVeeva eConsent gives us an easy-to-use solution that can keep up with our fast-paced environment and improve participant comprehension of study procedures. Deploying the solution went smooth, with positive feedback from study teams, on-site staff, and participants.\u201d <\/p>\n

A global leader in early clinical research services, Celerion uses Veeva SiteVault<\/a> to digitally author, manage, and distribute informed consent forms (ICF). Patients can then access the eConsent document securely and complete the consenting process via a mobile device. This simplifies document reconciliation and reduces the administrative burden on sites. With a seamless flow of information, Celerion has complete visibility into consent status for improved study compliance and oversight. <\/p>\n

\u201cCelerion is advancing how the industry works together by using digital solutions that enable patient-centric, paperless clinical trials,\u201d said Tim Davis, vice president, MyVeeva for Patients at Veeva Systems. \u201cVeeva eConsent improves the informed consent process for all parties involved by delivering an intuitive and digital experience for patients and easy collaboration with sites and IRBs for sponsors.\u201d<\/p>\n

Learn how Celerion modernized the patient consenting process at the upcoming Veeva R&D and Quality Summit Connect<\/a>, 14 October 2021. The online event is open to life sciences industry professionals. Register and stay up to date on program details at veeva.com\/Summit<\/a>. <\/p>\n

Additional Information<\/strong>
\nFor more on Veeva eConsent, visit: veeva.com\/eu\/eConsent<\/a>
\nConnect with Veeva on LinkedIn: linkedin.com\/company\/veeva-systems<\/a>
\nFollow @veeva_eu on Twitter: twitter.com\/veeva_eu<\/a><\/p>\n

About Veeva Systems<\/strong>
\nVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world\u2019s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com\/eu<\/a>.<\/p>\n

Forward-looking Statements<\/strong>
\nThis release contains forward-looking statements, including the market demand for and acceptance of Veeva\u2019s products and services, the results from use of Veeva\u2019s products and services, and general business conditions, particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva\u2019s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva\u2019s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva\u2019s financial results are included under the captions, \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations,\u201d in the company\u2019s filing on Form 10-Q for the period ended July 31, 2021. This is available on the company\u2019s website at veeva.com<\/a> under the Investors section and on the SEC\u2019s website at sec.gov<\/a>. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time. <\/p>\n

###<\/p>\n

Contact:<\/strong>\t<\/p>\n

Deivis Mercado
\nVeeva Systems
\n925-226-8821
\ndeivis.mercado@veeva.com<\/a><\/p>\n

Jeremy Whittaker
\nVeeva Systems
\n+49 6950955486
\njeremy.whittaker@veeva.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Veeva eConsent simplifies patient informed consent for greater efficiency and compliance.<\/p>\n","protected":false},"featured_media":60449,"parent":0,"template":"","class_list":["post-60375","resources","type-resources","status-publish","has-post-thumbnail","hentry","resource-area-20-clinical-operations","resource-area-20-research-sites","resource-area-20-vault-platform-area","resource-product-20-eisf","resource-product-20-sponsor-site-collaboration","resource-product-20-vault-platform","resource-type-news-press-release","resource-type-press-release"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/60375"}],"collection":[{"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/resources"}],"about":[{"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/types\/resources"}],"version-history":[{"count":1,"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/60375\/revisions"}],"predecessor-version":[{"id":60453,"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/60375\/revisions\/60453"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/media\/60449"}],"wp:attachment":[{"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/media?parent=60375"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}